Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
A Pilot Study to Assess Safety and Biomarker Responses of the Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
In the register
The register attaches this trial to Brepocitinib (Priovant Therapeutics), currently at “Phase 2/3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Emma Guttman
- Participants (registry)
- 51
- Start
- May 2021
- Primary completion
- September 2023
- Study completion
- September 2023
- Last registry update
- May 2026
- Countries
- United States
Conditions studied: Cicatricial Alopecia
Interventions: PF-06700841, Brepocitinib, Placebo
Other trials of Brepocitinib
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.